Huadao Biotech initiates IPO counseling: Chairman Yu Xuejun holds 31% of shares, with New Kaiyuan and Hankang Capital participating as investors

Rui Finance Liu Zhiying On March 27, Huadao (Shanghai) Biopharmaceutical Co., Ltd. (hereinafter referred to as “Huadao Biopharmaceutical”) completed IPO tutoring (advisory) filing with the Shanghai branch of the China Securities Regulatory Commission. It plans to list on the A-share market, and the tutoring institution is Ping An Securities Co., Ltd.

Huadao Biopharmaceutical was established in 2017. Its registered capital is 25.4014 million yuan, and its legal representative is Yu Xuejun. It is a biopharmaceutical company specializing in cell immunotherapy, with a particular focus on technology development and innovation across the full industrial chain of cellular drugs.

According to information on the CDE website, the company already has four CAR-T therapies approved for clinical use, covering both hematologic malignancies and solid tumors. In December 2025, its first CAR-T cell therapy targeting relapsed/refractory non-Hodgkin lymphoma was submitted to the National Medical Products Administration’s Center for Drug Evaluation for a marketing authorization application, with a price of more than 200,000 yuan.

It is worth noting that CAR-T cell therapy is widely acclaimed as an “anti-cancer wonder drug.” Huadao Biopharmaceutical’s pricing stands in sharp contrast to that of similar products already listed. Overseas, the pricing of similar drugs is generally in the range of USD 400k to USD 500k. In China, the prices of several products already approved for launch are also mostly between 1.0 million and 1.2 million yuan.

At present, Huadao Biopharmaceutical has five subsidiaries: Huadao Biopharmaceutical (Zhengzhou) Co., Ltd., Huadao Biopharmaceutical (Changchun) Co., Ltd., Huadao Biopharmaceutical (Chongqing) Co., Ltd., Shaanxi Huadao Biopharmaceutical Co., Ltd., and Huadao Pharmaceutical Technology (Shanghai) Co., Ltd.

In terms of equity, Huadao Biopharmaceutical’s controlling shareholder is the chairman, Yu Xuejun, with a shareholding ratio of 30.68%. In addition, New Source, HanKang Capital, Huarui Investment, Shanda Investment, and Heil Medical Technology hold stakes.

According to the materials, Yu Xuejun, the founder of Huadao Biopharmaceutical, graduated from Air Force Medical University and Naval Medical University. He had previously worked as a doctor in the Hematology Department at Shanghai Changhai Hospital (also known as the First Affiliated Hospital of Naval Medical University).